Market Place
Sourcing Support
Vaxart Announces Stockholders Meeting Results
13 Jun 2025 //
GLOBENEWSWIRE
Vaxart`s Second-Gen Vaccine Tech Shows Stronger Antibody Response
11 Jun 2025 //
GLOBENEWSWIRE
Vaxart to Host Call on June 11 to Discuss Phase I Trial Results
10 Jun 2025 //
GLOBENEWSWIRE
Vaxart Announces Adjournment of Annual Meeting of Stockholders
02 Jun 2025 //
GLOBENEWSWIRE
Vaxart`s Founder Provides Video Update to Stockholders
29 May 2025 //
GLOBENEWSWIRE
Vaxart at Jefferies Global Healthcare Conference on June 5, 2025
29 May 2025 //
GLOBENEWSWIRE
Vaxart Answers FAQs from Retail Investors
28 May 2025 //
GLOBENEWSWIRE
Vaxart Starts Dosing in 10,000-Participant Ph 2b COVID-19 Trial
27 May 2025 //
GLOBENEWSWIRE
Vaxart Announces Adjournment of Annual Meeting of Stockholders
21 May 2025 //
GLOBENEWSWIRE
Vaxart Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
20 May 2025 //
GLOBENEWSWIRE
Vaxart Approves Resolutions to Narrow Reverse Split Range
16 May 2025 //
GLOBENEWSWIRE
Vaxart approved to dose 10,000 in Phase 2b Covid-19 Trial
15 May 2025 //
GLOBENEWSWIRE
Vaxart Publishes Positive Phase 2b Norovirus Vaccine Results
14 May 2025 //
GLOBENEWSWIRE
Vaxart Reports First Quarter 2025 Financial Results
13 May 2025 //
GLOBENEWSWIRE
Vaxart Answers FAQs on Stock Split in Proxy Statement
12 May 2025 //
GLOBENEWSWIRE
Vaxart CEO Updates Stockholders on Company Progress
05 May 2025 //
GLOBENEWSWIRE
Vaxart to Host Q1 2025 Business Update and Financial Results Conf
02 May 2025 //
GLOBENEWSWIRE
Vaxart Completes Ph 1 Trial Enrollment for Norovirus Pill vaccine
30 Apr 2025 //
GLOBENEWSWIRE
Vaxart to Present at the Citizens Life Sciences Conference
30 Apr 2025 //
GLOBENEWSWIRE
Vaxart to Present at World Vaccine Congress Washington 2025
16 Apr 2025 //
GLOBENEWSWIRE
Vaxart Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
27 Mar 2025 //
GLOBENEWSWIRE
Vaxart lays off staffers after HHS demands halt to vaccine trial
21 Mar 2025 //
FIERCE BIOTECH
Vaxart Reports Full Year 2024 Financial Results
20 Mar 2025 //
GLOBENEWSWIRE
Vaxart to Host 2024 Business Update Call on March 20
13 Mar 2025 //
GLOBENEWSWIRE
Vaxart Starts Norovirus Oral Pill Vaccine Trial
11 Mar 2025 //
GLOBENEWSWIRE
Vaxart Announces Publication on Oral Norovirus Vaccine in Elderly
05 Mar 2025 //
GLOBENEWSWIRE
Vaxart Appoints Biotech Executive Kevin to Board of Directors
28 Jan 2025 //
GLOBENEWSWIRE
Vaxart Highlights Progress In COVID-19 And Norovirus Programs
14 Jan 2025 //
GLOBENEWSWIRE
Vaxart Announces Favorable DSMB Review For COVID-19 Phase 2b Trial
13 Jan 2025 //
GLOBENEWSWIRE
Vaxart Completes Enrollment In Phase 2b COVID-19 Oral Vaccine Study
02 Dec 2024 //
GLOBENEWSWIRE
Vaxart Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
19 Nov 2024 //
GLOBENEWSWIRE
Vaxart Business Update & Reports Q3 2024 Financial Results
13 Nov 2024 //
GLOBENEWSWIRE
Vaxart to Host Q3 2024 Financial Results & Business Update Call
07 Nov 2024 //
GLOBENEWSWIRE
Vaxart To Showcase COVID-19 And Norovirus Vaccines At Congress
24 Oct 2024 //
GLOBENEWSWIRE
Vaxart To Present Norovirus Data At IDWeek 2024
15 Oct 2024 //
GLOBENEWSWIRE
Vaxart Initiates Sentinel Cohort For Ph 2b COVID-19 Pill Vaccine
30 Sep 2024 //
GLOBENEWSWIRE
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 Aug 2024 //
GLOBENEWSWIRE
Vaxart Reports Q2 2024 Results And Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Vaxart To Host Q2 2024 Business Update Call On August 8
02 Aug 2024 //
GLOBENEWSWIRE
Vaxart provides business update
17 Jun 2024 //
GLOBENEWSWIRE
Vaxart wins $453M in BARDA funding for oral Covid-19 vaccine
14 Jun 2024 //
ENDPTS
Vaxart Gets BARDA Award Up To $453M For COVID-19 Oral Pill Vaccine Study
13 Jun 2024 //
GLOBENEWSWIRE
Vaxart Announces $40M Underwritten Common Stock Offering
13 Jun 2024 //
GLOBENEWSWIRE
More US bird flu spread would heighten human infection risk, officials say
13 Jun 2024 //
REUTERS
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23 May 2024 //
GLOBENEWSWIRE
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
13 May 2024 //
GLOBENEWSWIRE
Vaxart To Host Q1 2024 Business Update And Earnings Call On May 13
07 May 2024 //
GLOBENEWSWIRE
Vaxart: Positive Bivalent Norovirus Vaccine Data In Lactating Mothers
30 Apr 2024 //
GLOBENEWSWIRE
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
27 Mar 2024 //
GLOBENEWSWIRE
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 Mar 2024 //
GLOBENEWSWIRE
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference
07 Mar 2024 //
GLOBENEWSWIRE
Vaxart Appoints Steven Lo as President, Chief Executive Officer, and Director
06 Mar 2024 //
GLOBENEWSWIRE
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data
05 Feb 2024 //
GLOBENEWSWIRE
Vaxart Receives $9.27 Million BARDA Project NextGen Award
19 Jan 2024 //
GLOBENEWSWIRE
Vaxart, Inc. Announces Management Change
16 Jan 2024 //
GLOBENEWSWIRE
Vaxart Announces $10.0M Registered Direct Offering with RA Capital Management
16 Jan 2024 //
GLOBENEWSWIRE
Vaxart Announces Last Subject Dosed in Phase 1 of Norovirus Vaccine Candidate
21 Dec 2023 //
GLOBENEWSWIRE
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate
02 Nov 2023 //
GLOBENEWSWIRE
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
